Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Blood (2025) 146 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2025-1737

Published: 2025

Journal Articles

The Importance of the Number of Transplanted Cells with Dipeptidyl Peptidase-4 Expression on the Hematopoietic Recovery and Lymphocyte Reconstitution in Patients with Multiple Myeloma after Autologous Hematopoietic Stem-Cell Transplantation

Anna Kopinska, Malgorzata Krawczyk-Kulis, Joanna Dziaczkowska-Suszek, Katarzyna Bieszczad, Krystyna Jagoda, Slawomira Kyrcz-Krzemien, Prof

Blood (2015) 126 (23): 5415.

https://doi.org/10.1182/blood.V126.23.5415.5415

Published: 2015

Journal Articles

CD26+ (dipeptidyl peptidase IV positive) Cells In Harvest Material For Multiple Myeloma Autotransplantation

Anna Kopinska, Malgorzata Krawczyk-Kulis, Joanna Suszek-Dziaczkowska, Katarzyna Bieszczad, Krystyna Jagoda, Slawomira Kyrcz-Krzemien, MD

Blood (2013) 122 (21): 5445.

https://doi.org/10.1182/blood.V122.21.5445.5445

Published: 2013

Journal Articles

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Blood (2010) 116 (21): 2138.

https://doi.org/10.1182/blood.V116.21.2138.2138

Published: 2010

Journal Articles

Minimal Residual Disease Status Is the Most Important Preditive Factor in Adults with Acute Lymphoblastic Leukemia. Prospective, Multicenter PALG 4-2002 MRD Study.

Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, Sebastian Giebel, Krystyna Jagoda, Beata Stella-Holowiecka, Beata Jakubas, Monika Paluszewska, Ilona Seferynska, Anna Czyz, Wlodzimierz Mendrek, Aleksander Skotnicki, Wieslaw W. Jedrzejczak, Krzysztof Warzocha, Lech Konopka, Andrzej Hellmann

Blood (2007) 110 (11): 2821.

https://doi.org/10.1182/blood.V110.11.2821.2821

Published: 2007

Journal Articles

Immunophenotyping to Detect Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia - Feasibility and Prognostic Significance.

Jerzy Holowiecki, Sebastian Giebel, MD, Krystyna Jagoda, PhD, Malgorzata Krawczyk-Kulis, MD, Beata Stella-Holowiecka, MD, Slawomira Kyrcz-Krzemien, MD, Monika Paluszewska, MD, Malgorzata Kopera, MD, Wlodzimierz Medrek, MD, Grazyna Bober, MD, Jacek Najda, MD

Blood (2004) 104 (11): 4489.

https://doi.org/10.1182/blood.V104.11.4489.4489

Published: 2004

Journal Articles

Independent Prognostic Significance of Cytogenetics, Immunophenotype, Tumor Burden, and Age in Acute Myeloid Leukemia. Analysis of Patients Treated within PALG 1999 Prospective, Randomized Study.

Sebastian Grosicki, MD, Jerzy Holowiecki, Sebastian Giebel, MD, Olga Haus, MD, Beata Stella-Holowiecka, MD, Krystyna Jagoda, Aleksandra Bartkowska-Chrobok

Blood (2004) 104 (11): 4395.

https://doi.org/10.1182/blood.V104.11.4395.4395

Published: 2004

Journal Articles

Single Immunophenotypical Evaluation of Minimal Residual Disease before Autotransplantation of Non-Cryopreserved Bone Marrow Is Insufficient for Prediction of Outcome in High Risk Adult Acute Lymphoblastic Leukemia.

Beata M. Stella-Holowiecka, MD, Krystyna Jagoda, MD, Aleksandra M. Holowiecka-Goral, MD, Tomasz Czerw, MD, Sebastian Giebel, MD, Malgorzata Krawczyk-Kulis, MD, Jerzy Holowiecki, MD, PhD

Blood (2004) 104 (11): 4439.

https://doi.org/10.1182/blood.V104.11.4439.4439

Published: 2004

Journal Articles

CD52 and CD20 as Potential Targets for Anti-Leukemic Immunotherapy in Adult Acute Lymphoblastic Leukemia.

Krystyna Jagoda, PhD, Sebastian Giebel, MD, Beata Stella-Holowiecka, MD, Malgorzata Krawczyk-Kulis, MD, Jerzy Holowiecki

Blood (2004) 104 (11): 4403.

https://doi.org/10.1182/blood.V104.11.4403.4403

Published: 2004

Journal Articles

Time-Sequenced G-CSF (Lenograstim) for the Treatment of Adult Acute Lymphoblastic Leukemia - Seven Year Follow-Up of the Polish Adult Leukemia Group 4–96 Study.

Sebastian Giebel, MD, Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, MD, Slawomira Kyrcz-Krzemien, MD, Andrzej Hellmann, Anna Dmoszynska, Monika Paluszewska, MD, Tadeusz Robak, Lech Konopka, Ilona Seferynska, MD, Aleksander Skotnicki, Wojciech Baran, MD, Maria Adamczyk-Cioch, MD, Agata Wrzesien-Kus, MD, Krystyna Jagoda, PhD

Blood (2004) 104 (11): 2733.

https://doi.org/10.1182/blood.V104.11.2733.2733

Published: 2004

Journal Articles

The Impact of Immunosuppressive Therapy on an Early Quantitative Reconstitution of NK Cells after Allogeneic Hematopoietic Stem Cell Transplantation.

Sebastian Giebel, MD, Joanna Dziaczkowska, PhD, Iwona Wylezol, MD, Jerzy Wojnar, MD, Malgorzata Krawczyk-Kulis, MD, Krystyna Jagoda, PhD, Aleksandra Holowiecka-Goral, MD, Jerzy Holowiecki

Blood (2004) 104 (11): 4946.

https://doi.org/10.1182/blood.V104.11.4946.4946

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

The Importance of the Number of Transplanted Cells with Dipeptidyl Peptidase-4 Expression on the Hematopoietic Recovery and Lymphocyte Reconstitution in Patients with Multiple Myeloma after Autologous Hematopoietic Stem-Cell Transplantation

CD26+ (dipeptidyl peptidase IV positive) Cells In Harvest Material For Multiple Myeloma Autotransplantation

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Minimal Residual Disease Status Is the Most Important Preditive Factor in Adults with Acute Lymphoblastic Leukemia. Prospective, Multicenter PALG 4-2002 MRD Study.

Immunophenotyping to Detect Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia - Feasibility and Prognostic Significance.

Independent Prognostic Significance of Cytogenetics, Immunophenotype, Tumor Burden, and Age in Acute Myeloid Leukemia. Analysis of Patients Treated within PALG 1999 Prospective, Randomized Study.

Single Immunophenotypical Evaluation of Minimal Residual Disease before Autotransplantation of Non-Cryopreserved Bone Marrow Is Insufficient for Prediction of Outcome in High Risk Adult Acute Lymphoblastic Leukemia.

CD52 and CD20 as Potential Targets for Anti-Leukemic Immunotherapy in Adult Acute Lymphoblastic Leukemia.

Time-Sequenced G-CSF (Lenograstim) for the Treatment of Adult Acute Lymphoblastic Leukemia - Seven Year Follow-Up of the Polish Adult Leukemia Group 4–96 Study.

The Impact of Immunosuppressive Therapy on an Early Quantitative Reconstitution of NK Cells after Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only